Status and phase
Conditions
Treatments
About
A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
Full description
Allocetra-OTS is an immunomodulatory cell-based therapy consisting of allogeneic peripheral blood mononuclear cells that have been modified to be engulfed by macrophages and reprogram them into their homeostatic state.
This is a multi-center, randomized, placebo-controlled, dose-finding study comparing the efficacy, safety and tolerability of different dosing regimens of Allocetra-OTS, in patients with sepsis. The study aims to compare the safety and efficacy of different doses and regimens of Allocetra-OTS, as well as the clinical manifestations following Allocetra-OTS treatment, to that of Placebo in the treatment of organ failure in adult sepsis patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male or female ≥18 years and ≤90 years of age.
Meets Sepsis 3 criteria with a SOFA score ≥5 above pre-admission status
Sepsis due to infection in at least one of the below organs:
3.1. Community-Acquired Pneumonia (CAP). 3.2. Urinary tract infection 3.3. Acute cholecystitis diagnosed by Tokyo criteria 3.4. Acute cholangitis diagnosed by Tokyo criteria 3.5. Other intra-abdominal infections (IAI) 3.6. Skin or soft tissue infection
Adequate source control
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
160 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Talia Schloss
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal